Assessment of cardiovascular issues in cancer patients on immune checkpoint inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate patients who are suspected of experiencing cardiovascular events while undergoing treatment with immune checkpoint inhibitors. It involves a longitudinal prospective cohort design at a single center, where patients referred to the cardio-oncology unit will be assessed for conditions such as heart failure, atherosclerosis, and myocarditis. The study will document patient characteristics, diagnostic investigations, and outcomes following a multidisciplinary review. The goal is to better understand the cardiovascular complications associated with these cancer treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* all patient referred to the cardio oncology unit for suspected immune related cardiovascular complication on immune checkpoint inhibitors

Exclusion Criteria:

* none

Where it's running

• Intitut Mutualiste Montsouris
  Paris, France Recruiting

Study contacts

• Principal investigator: Mariana Mirabel, MD, PhD — Institut Mutualiste Montsouris
• Study coordinator: Isabelle Sauret
• Email: isabelle.sauret@imm.fr
• Phone: +33156616705

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thymosin Alpha-1 plus PD-1 therapy in older adults with advanced melanoma

  This trial tests whether adding Thymosin Alpha-1 to a PD-1 antibody helps people age 60 and up with advanced melanoma.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07644897

• Granzyme B-PET to see if immunotherapy works in TNBC

  This study will test whether a Granzyme B PET/CT scan can help predict how well immunotherapy will work for adults with locally advanced or metastatic triple-negative breast cancer receiving an immune checkpoint inhibitor.

  Recruiting Fudan University · Shanghai · NCT07705438

• Mycophenolate mofetil with prednisone for immune-related hepatitis from cancer therapy

  This study tests whether starting mycophenolate mofetil plus prednisone can help liver inflammation caused by immune checkpoint inhibitors in adults with moderate to severe immune-related hepatitis.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07663422

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Cardiovascular Outcomes After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors

  This study tests how often and what kinds of cardiovascular problems occur after adrenalectomy for pheochromocytoma or non-secreting tumors.

  Recruiting Central Hospital, Nancy, France · Vandœuvre-lès-Nancy, Lorraine · NCT07200245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.